Showing results (221-230 of 235) with videos related to
Sort By:
Pageof 24
The New England Journal of Medicine|December 12, 2017
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's LymphomaJoseph M Connors, Wojciech Jurczak, David J Straus, et al.The Lancet. Haematology|June 6, 2024
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trialJillian R Gunther, Jie Xu, Manoop S Bhutani, et al.Annals of Hematology|July 25, 2021
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter studyWon Seog Kim, Yasuhiro Oki, Seok Jin Kim, et al.Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell LymphomaMark W Clemens, L Jeffrey Medeiros, Charles E Butler, et al.Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell LymphomaLoretta J Nastoupil, Clark R Andersen, Amy Ayers, et al.The Lancet. Oncology|February 14, 2016
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysisSeok Jin Kim, Dok Hyun Yoon, Arnaud Jaccard, et al.Blood|April 14, 2026
Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with ImmunochemotherapyProkop Vodička, Tarec C El-Galaly, Vit Prochazka, et al.Pageof 24